Our pipeline

Mereo Discover Our Pipeline

At Mereo, we unlock the potential of rare disease and tumor therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.

We have already delivered four successful Phase 2 studies and a Phase 1b/2 ongoing. Our pipeline currently consists of six clinical-stage product candidates. Click below to see the relevant scientific publications for our products. 

Core programs

Product

Setrusumab (BPS804)

For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.

Product

Alvelestat (MPH966)

For the potential treatment of severe Alpha-1 Antitrypsin Deficiency-Related Lung Disease (AATD-LD) and Bronchiolitis Obliterans Syndrome (BOS).

Product

Etigilimab (MPH313)

For the potential treatment of patients with advanced or metastatic
solid tumors.

Core programs

Partnered and Partnering Opportunities on Non-Core Programs

We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna. 

Product

Navicixizumab (OMP305B83)

For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.

Product

Acumapimod (BCT197)

For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).

Product

Leflutrozole (BGS649)

For the potential treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).

Partnered and partnering opportunities on non-core programs

Pipeline News

Image
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
12 September 2022

Mereo BioPharma Group today reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors. These biomarker data were presented at a poster session at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting on September 10, 2022.

Image
Mereo BioPharma and Ultragenyx to Present Setrusumab Data Update at ASBMR
09 September 2022

Mereo BioPharma and Ultragenyx Pharmaceutical Inc. today announced that additional data relevant to setrusumab will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR) being held September 9-12, 2022, in Austin, Texas.

Image
Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
02 June 2022

Mereo BioPharma today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE). The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022. The Company also provided an update on its capital allocation and portfolio prioritization plan.

Image
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
26 May 2022

Mereo BioPharma today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.